Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Quality control method and kit for detecting human KRAS gene variation based on high-throughput sequencing

A gene mutation and kit technology, which is used in the determination/inspection of microorganisms, biochemical equipment and methods, DNA/RNA fragments, etc., to reduce the cost of detection quality control and improve the efficiency.

Inactive Publication Date: 2017-03-15
3D BIOMEDICINE SCI & TECH CO LTD
View PDF1 Cites 10 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0007] At present, there are no quality control products and kits for human circulating tumor DNA KRAS gene sequencing detection in China

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Quality control method and kit for detecting human KRAS gene variation based on high-throughput sequencing
  • Quality control method and kit for detecting human KRAS gene variation based on high-throughput sequencing
  • Quality control method and kit for detecting human KRAS gene variation based on high-throughput sequencing

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0039] Example 1: Preparation of Quality Control Products for Human Circulating Tumor DNA KRAS Gene Variation Detection

[0040] 1.1. Seven commonly used stable human tumor cell lines HOP-62, HCT-15, AGS, NCI-H1573, COR-L23, NCI-H1355 and SW1417 were purchased from ATCC. The genomic DNA of each cell line was sequenced by the Sanger method, and the heterozygous and homozygous mutation sites confirmed by the Sanger method were used as positive control sites. It has been verified that there are 6 positive mutation sites in total.

[0041] 1.2. The seven human tumor cell lines were cultured in a special medium, culture conditions: 37°C constant temperature, 5% CO 2 , humidity 50%. Cultivate until the cell density reaches 80-90% of the area of ​​the culture dish, collect the cells in the logarithmic phase of growth, centrifuge at 1500g at 4°C for 5min, take the precipitate and discard the supernatant.

[0042] 1.3. Resuspend in pre-cooled PBS solution, centrifuge at 5000rpm at 4...

Embodiment 2

[0046] Example 2: Preparation of Human Circulating Tumor DNA KRAS Gene Variation Detection Kit

[0047] 2.1. Design and synthesize multiple capture probes for different target regions on the human circulating tumor DNA KRAS gene. The collection of all capture probes can cover all coding exon regions and exon-intron junction regions of the human KRAS gene; The capture probe is labeled with biotin; the sequence of the capture probe is shown in SEQ ID NO: 1-37 in the sequence listing.

[0048] 2.2. Mix all the capture probes shown in SEQ ID NO: 1-37 in the sequence listing together in the same ratio, and dilute the mixture to a working concentration of 1.5 PM (PM = picomole / liter), and store at -20°C.

[0049] 2.3. Separately pack the capture probe mixture and the quality control obtained in Example 1.

[0050] 2.4. Prepare instructions, outer packaging, assemble and seal.

[0051] 2.5. The amount of capture probe mixture used is 6 μL / 3 reactions, 12 μL / 6 reactions, 24 μL / 12 re...

Embodiment 3

[0052] Example 3: Sequencing detection of human circulating tumor DNA KRAS gene variation

[0053] The instrument used for sequencing in this example is NextSeq CN500, an automatic gene sequence analyzer, and high-throughput sequencing was performed on the Illumina platform.

[0054] The preparation method of the quality control product is the same as that in Example 1.

[0055] 3.1. Human cfDNA was extracted from 10 positive plasma samples, and quality control products were used directly without extraction.

[0056] 3.2. Library construction

[0057] 3.2.1. End Repair

[0058] Add 30ng of extracted cfDNA sample or quality control to 0.2ml PCR reaction tube, make up to 50μL with Low EDTA TE, vortex to mix, and centrifuge briefly. Add 1 μL of end-repair enzyme mixture and 6 μL of end-repair reaction buffer, vortex and mix briefly, and then incubate at 37°C for 5 minutes, then incubate at 65°C for 30 minutes, and then at 37°C for 5 minutes for end-repair. After the reaction,...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention relates to a quality control method and a kit for detecting human KRAS gene variation based on high-throughput sequencing, and application thereof. The quality control method comprises the following steps of extracting a plurality of genomic DNA (deoxyribonucleic acid) of a human tumor cell system with positive KRAS gene variation; measuring a positive variation site as a positive contrast site by a Sanger sequencing method; performing segmenting on the genomic DNA, and mixing according to certain ratio, so as to obtain a quality control product for detecting the human KRAS gene variation based on the high-throughput sequencing. The kit comprises the quality control product for detecting the human KRAS gene variation.

Description

[0001] field of invention [0002] The invention relates to the field of gene detection, in particular to a quality control method and a kit for detecting DNAKRAS gene variation of human circulating tumors based on high-throughput sequencing. Background technique [0003] There are free small fragments of DNA (cell-free DNA, cfDNA) in the blood, which come from dead cells. Usually dead cells will be removed, so the content of cfDNA is very low, usually 25ng cfDNA in 1mL plasma of a healthy person. The content of cfDNA in cancer patients is several times higher than normal, and part of it is ctDNA (circulating tumor DNA). The relative content of ctDNA is correlated with tumor burden and response to treatment, and can be used to identify driver genes, guide clinical treatment, monitor clinical treatment effects and cancer recurrence, reveal treatment resistance, and detect disease progression. In some respects the sensitivity of ctDNA method is even higher than traditional mea...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): C12Q1/68C12N15/11
CPCC12Q1/6858C12Q1/6869C12Q1/6886C12Q2600/156C12Q2600/166C12Q2545/113C12Q2535/101C12Q2535/122
Inventor 李福根熊磊金其煌汤先念
Owner 3D BIOMEDICINE SCI & TECH CO LTD
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com